Clinical Trial

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Investigator
Complete title:
A Phase 1a/1b, Open Label First-in-Human Study of The Safety, Tolerability and Feasibility of Gene Edited Autologous NeoTCR T Cells Administered as a Single Agent or in Combination with Anti-PD-1 to Patients with Locally Advanced or Metastatic Solid Tumors
Trial phase:
Phase I
Study ID:
NCT03970382
Local study ID:
RG1006989
Summary:
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
Trial keywords:
Solid Tumors
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
phone 1-800-606-7800
Toll-free